Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Trial details
- Registry ID
- NCT04229979
- Phase
- Phase 3
The FDA approved Azacitidine on 19 May 2004.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Sellas Life Sciences Group | Phase 3 | Active not recruiting | 2025-12Estimated |
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716 | Aprea Therapeutics | Phase 3 | Completed | 2020-11-27Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2004-05-19Day | Azacitidine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA050794", "applicant_as_listed_by_fda": "BRISTOL-MYERS", "brand_names": ["VIDAZA"], "active_ingredients": ["AZACITIDINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20040519", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |